IMUX IMMUNIC, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1280776 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-24.5%
TTM EPS YoY135.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-223.2%
ROA-144.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.4%
Debt / equity0.00x
Current ratio4.28x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-36.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $81.98M | $80.05M | $83.22M | $71.25M | $61.12M |
| SG&A expense | $21.25M | $18.01M | $16.01M | $15.26M | $13.30M |
| Operating income | -$103.23M | -$98.05M | -$99.22M | -$119.49M | -$91.67M |
| Income tax | $0 | — | — | — | — |
| Net income | -$97.17M | -$100.51M | -$93.61M | -$120.41M | -$92.94M |
| EBITDA | -$103.06M | -$97.92M | -$99.11M | -$119.41M | -$91.58M |
| EPS (basic) | -0.62 | -1.00 | -2.11 | -3.78 | -3.93 |
| EPS (diluted) | -0.62 | -1.00 | -2.11 | -3.78 | -3.93 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 155.69M | 100.17M | 44.32M | 31.82M | 23.65M |
| Banking | |||||
| Provision for credit losses | $497,000 | $234,000 | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $15.48M | $35.67M | $46.67M | $106.75M | $86.86M |
| Current assets | $22.87M | $39.33M | $52.53M | $125.86M | $104.99M |
| PP&E, net | $608,000 | $545,000 | $466,000 | $294,000 | $152,000 |
| Goodwill | — | — | — | $0 | $32.97M |
| Total assets | $24.05M | $40.87M | $54.30M | $127.75M | $139.10M |
| Current liabilities | $30.62M | $22.18M | $24.73M | $13.08M | $11.40M |
| Total liabilities | $30.73M | $22.44M | $25.37M | $14.07M | $11.98M |
| Shareholders' equity | -$6.67M | $18.43M | $28.93M | $113.68M | $127.11M |
| Shares outstanding | 15.88M | 90.15M | 45.18M | 39.31M | 26.34M |
| Cash flow statement | |||||
| Operating cash flow | -$85.81M | -$84.77M | -$70.83M | -$65.14M | -$83.23M |
| Capital expenditure | $161,000 | $264,000 | $334,000 | $112,000 | $67,000 |
| Free cash flow | -$85.97M | -$85.03M | -$71.16M | -$65.26M | -$83.30M |
| Investing cash flow | -$161,000 | -$264,000 | $9.46M | -$9.74M | -$67,000 |
| Financing cash flow | $65.58M | $74.54M | $1.03M | $95.76M | $42.84M |
| Depreciation & amortization | $168,000 | $134,000 | $111,000 | $77,000 | $85,000 |
| Stock-based compensation | $8.86M | $8.53M | $7.10M | $7.93M | $5.95M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.